BNGO vs. PRE, RPID, OMIC, HLTH, AXDX, SEER, AKYA, TARA, FHLT, and PTWO
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Singular Genomics Systems (OMIC), Cue Health (HLTH), Accelerate Diagnostics (AXDX), Seer (SEER), Akoya Biosciences (AKYA), Protara Therapeutics (TARA), Future Health ESG (FHLT), and Pono Capital Two (PTWO). These companies are all part of the "medical" sector.
Bionano Genomics (NASDAQ:BNGO) and Prenetics Global (NASDAQ:PRE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.
Bionano Genomics presently has a consensus target price of $4.00, suggesting a potential upside of 250.88%. Prenetics Global has a consensus target price of $9.00, suggesting a potential upside of 55.07%. Given Bionano Genomics' higher possible upside, research analysts clearly believe Bionano Genomics is more favorable than Prenetics Global.
Prenetics Global has lower revenue, but higher earnings than Bionano Genomics. Prenetics Global is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bionano Genomics had 1 more articles in the media than Prenetics Global. MarketBeat recorded 3 mentions for Bionano Genomics and 2 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 0.00 beat Bionano Genomics' score of -0.16 indicating that Prenetics Global is being referred to more favorably in the news media.
Prenetics Global has a net margin of -193.60% compared to Bionano Genomics' net margin of -605.26%. Prenetics Global's return on equity of -11.15% beat Bionano Genomics' return on equity.
Bionano Genomics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Prenetics Global has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500.
11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 25.0% of Prenetics Global shares are held by institutional investors. 2.4% of Bionano Genomics shares are held by insiders. Comparatively, 7.8% of Prenetics Global shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Bionano Genomics received 157 more outperform votes than Prenetics Global when rated by MarketBeat users. However, 83.33% of users gave Prenetics Global an outperform vote while only 64.80% of users gave Bionano Genomics an outperform vote.
Summary
Prenetics Global beats Bionano Genomics on 11 of the 18 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
